Article

The prevalence of urinary incontinence in women in four European countries.

Section for General Practice, Department of Public Health and Primary Health Care, University of Bergen, Norway.
BJU International (Impact Factor: 3.13). 03/2004; 93(3):324-30. DOI: 10.1111/j.1464-410X.2003.04609.x
Source: PubMed

ABSTRACT To determine the prevalence, type and treatment behaviour of women with urinary incontinence in four European countries.
Data were collected using a postal survey which was sent to 29,500 community-dwelling women aged > or = 18 years in France, Germany, Spain and the UK. Subjects were asked about the type of urinary incontinence they had experienced and their treatment behaviour.
Of the women who responded, 35% reported involuntary loss of urine in the preceding 30 days; stress urinary incontinence was the most prevalent type. The lowest prevalence was in Spain (23%), while the prevalence was 44%, 41% and 42% for France, Germany and the UK, respectively. About a quarter of women with urinary incontinence in Spain (24%) and the UK (25%) had consulted a doctor about it; in France (33%) and Germany (40%) the percentages were higher. Overall, <5% of the women had ever undergone surgery for their condition. While pads were used by half of the women, there were some differences among the countries.
Millions of women in Europe have urinary incontinence; the consultation and treatment rates were low in the European countries included in this study.

0 Bookmarks
 · 
114 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Wenn die Blase nicht mehr dicht hält, ist das für die Betroffenen eine enorme Belastung. Dennoch ist dieses Thema für viele immer noch tabu. Wenn Ihnen eine Patientin aber Ihre Blasenprobleme anvertraut, sollten Sie bei der Abklärung der Ursachen Sorgfalt walten lassen. Denn die richtige Diagnose entscheidet über die geeigneten therapeutischen Maßnahmen.
    MMW Fortschritte der Medizin 06/2012; 154(25-26):83-87. DOI:10.1007/s15006-012-0773-0
  • [Show abstract] [Hide abstract]
    ABSTRACT: Voiding dysfunction encompasses a wide range of urologic disorders including stress urinary incontinence and overactive bladder that have a detrimental impact on the quality of life of millions of men and women worldwide. In recent years, we have greatly expanded our understanding of the pathophysiology of these clinical conditions. However, current gold standard therapies often provide symptomatic relief without targeting the underlying etiology of disease development. Recently, the use of stem cells to halt disease progression and reverse underlying pathology has emerged as a promising method to restore normal voiding function. Stem cells are classically thought to aid in tissue repair via their ability for multilineage differentiation and self-renewal. They may also exert a therapeutic effect via the secretion of bioactive factors that direct other stem and progenitor cells to the area of injury, and that also possess antiapoptotic, antiscarring, neovascularization, and immunomodulatory properties. Local injections of mesenchymal, muscle-derived, and adipose-derived stem cells have all yielded successful outcomes in animal models of mechanical, nerve, or external urethral sphincter injury in stress urinary incontinence. Similarly, direct injection of mesenchymal and adipose-derived stem cells into the bladder in animal models of bladder overactivity have demonstrated efficacy. Early clinical trials using stem cells for the treatment of stress urinary incontinence in both male and female patients have also achieved promising functional results with minimal adverse effects. Although many challenges remain to be addressed prior to the clinical implementation of this technology, novel stem-cell-based therapies are an exciting potential therapy for voiding dysfunction.
    Therapeutic Advances in Urology 02/2015; 7(1):22-40. DOI:10.1177/1756287214553968
  • Source
    Musa Saraçoğlu, Hakan Öztürk, Mine Genç, Esin Çelik
    [Show abstract] [Hide abstract]
    ABSTRACT: Stres inkontinans yüksek prevalansı ve yaşam kalitesine olumsuz etkileri nedeniyle önemini korumakta olan bir hastalıktır. Tedavisinde öncelikle cerrahi yöntemler kullanılmaktadır. Bununla birlikte haftada 15 den daha az sayıda inkontinans atağı olan hafif ve orta şiddetteki olgular için cerrahi dışı tedavi yöntemleri önerilmektedir. Ameliyat olamayan ya da ameliyatı istemeyen hastalar için de cerrahi dışı yöntemler bir seçenek olabilmektedir. Cerrahi dışı tedavi seçeneklerinden birisi de farmakoterapidir. Bu amaçla kullanılan ilaçların başlıcaları alfa reseptör agonitleri, beta reseptör agonistleri, beta reseptör antagonistleri, serotonin-adrenalin geri alım inhibitörleri ve östrojenlerdir. Bu ilaçlar içerisinde stres inkontinans tedavisi için onay alan tek ilaç duloksetindir. Bu makalede diğer ajanlarla birlikte duloksetin tedavisinin özellikleri ve dikkat edilmesi gereken noktalar ele alınmıştır. Abstract: Stress incontinence maintains its importance due to its high prevalence and the negative influence on the quality of life. Surgical approaches are primarily used in its treatment. However, treatment approaches other than surgical methods are recommended in patients with mild to moderate disease that manifest with less than 15 incontinence episodes per week. Non-surgical methods also offer an alternative approach to patients in whom the surgery is contraindicated or in patients who do not wish to undergo a surgery. Pharmacotherapy is one of the non-surgical means of therapy. The major drugs used for this purpose include alpha receptor agonists, beta receptor antagonists, serotonin-adrenaline re-uptake inhibitors, and estrogen. Among these agents, duloxetine is the only drug that has obtained approval for the treatment of stress incontinence. The features of duloxetine therapy together with the other agents and the important aspect to be considered are discussed in this manuscript.

Preview

Download
9 Downloads
Available from